Literature DB >> 25354045

Acromegaly and bone disease.

Jeremy R Anthony1, Adriana G Ioachimescu.   

Abstract

PURPOSE OF REVIEW: To provide an update on current understanding of osteoporosis associated with acromegaly. RECENT
FINDINGS: Patients with acromegaly have an increased risk of morphometric vertebral fractures. This seems to correlate with acromegaly activity and its duration, but it persists after biochemical control is achieved. Coexistent hypogonadism, diabetes mellitus and over-replacement with glucocorticoids have additional detrimental effects. Bone mineral density can be normal, increased or decreased, and is usually discordant with occurrence of fractures. However, a decrease in the hip bone mineral density during follow-up has been associated with development of new vertebral fractures. Bone turnover markers are increased and tend to normalize after biochemical control of acromegaly. Hypercalcemia rarely occurs in acromegaly and may be parathyroid hormone-dependent or 1,25 dihydroxy-vitamin D dependent. The latter improves with biochemical control of acromegaly.
SUMMARY: Screening with thoracic and lumbar vertebral radiographs is indicated in patients with acromegaly. We recommend biochemical control of acromegaly, treatment of hypogonadism and other risk factors of osteoporosis and avoiding supraphysiologic doses of glucocorticoids. Further studies are needed to understand mechanisms of skeletal fragility in acromegaly and clinical impact of vertebral fractures. Further studies of tailored therapy for patients with acromegaly and osteoporosis are also needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25354045     DOI: 10.1097/MED.0000000000000109

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  6 in total

Review 1.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

Review 2.  Rare causes of osteoporosis.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

Review 3.  [Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].

Authors:  S Petersenn; M Christ-Crain; M Droste; R Finke; J Flitsch; I Kreitschmann-Andermahr; A Luger; J Schopohl; G Stalla
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

4.  Patients with Active Acromegaly are at High Risk of 25(OH)D Deficiency.

Authors:  Jowita Halupczok-Żyła; Aleksandra Jawiarczyk-Przybyłowska; Marek Bolanowski
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-02       Impact factor: 5.555

Review 5.  Acromegaly and non-parathyroid hormone-dependent hypercalcemia: a case report and literature review.

Authors:  Shaomin Shi; Lan Zhang; Yerong Yu; Chun Wang; Jianwei Li
Journal:  BMC Endocr Disord       Date:  2021-05-01       Impact factor: 3.263

6.  Preoperative and Postoperative Bone Mineral Density Change and Risk Factor Analysis in Patients with a GH-Secreting Pituitary Adenoma.

Authors:  Li'nan Qin; Xiaopeng Guo; Lu Gao; Zihao Wang; Chenzhe Feng; Kan Deng; Wei Lian; Bing Xing
Journal:  Int J Endocrinol       Date:  2019-11-03       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.